Senti Biosciences Holdings Inc

USD0.0001
Create an alert
Sell
0.00p
Buy
0.00p
No change
Last updated today at

To trade with this investment contact our helpdesk

Online trading unavailable

Back to dashboard

Company Information

About this company

Senti Biosciences Holdings, Inc. is a wholly owned subsidiary of Senti Holdings, Inc. Senti Biosciences, Inc. is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. Its lead product candidate, SENTI-202, is a potentially first-in-class Logic Gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers currently being studied in an open-label, multi-center Phase I clinical trial for the treatment of relapsed/refractory hematological malignancies, including Acute Myeloid Leukemia.

Key people

Kanya Rajangam
President, Head - Research and Development, Chief Medical Officer
Timothy Lu
Chief Executive Officer, Director
Jay Cross
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
Bryan Baum
Director
Donald Tang
Director
James J. Collins
Independent Director
Feng Hsiung
Independent Director
Frances D. Schulz
Independent Director
Click to see more

Key facts

  • Shares in issue
    2.60m
  • EPIC
    SNTI
  • ISIN
    US8169441024
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • Market cap
    GBX 0.00
  • Employees
    39
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview of the company, currency, shares in issue, EPIC, location, exchange, index, website, Data sourced by LSEG. Objective, Costs, Fee Structure, Key facts including Benchmark, Gross gearing are provided by MorningStar.